Veno‐occlusive Disease of the Liver After Chemotherapy for Rhabdomyosarcoma: Case Report With a Review of the Literature

Kanwar, Vikramjit S.; Albuquerque, Maria Luiza C.; Ribeiro, Raul C.; Kauffman, William M.; Furman, Wayne L.

doi:10.1002/mpo.2950240513

Cited by 22 publications

(15 citation statements)

References 24 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It usually occurs within the first 3 weeks of marrow infusion. Risk factors for post-transplant VOD are pre-transplant hepatitis, age over 15 years, and underlying malignancy [2,3].…”

Section: Introductionmentioning

confidence: 99%

MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation

Bosch¹,

Hoe

2000

European Radiology

View full text Add to dashboard Cite

The aim of this study was to describe the MRI features of veno-occlusive disease (VOD) following bone-marrow transplantation in two patients. The MRI features consisted of hepatomegaly, hepatic vein narrowing, periportal cuffing, gallbladder wall thickening, marked hyperintensity of the gallbladder wall on T2-weighted images, ascites, and pleural effusion. In one patient, signs of reduced portal venous flow velocity were also observed. It is concluded that the use of MRI as a complementary technique following non-conclusive US examination enabled a timely diagnosis of this life-threatening disease in both patients.

show abstract

“…It usually occurs within the first 3 weeks of marrow infusion. Risk factors for post-transplant VOD are pre-transplant hepatitis, age over 15 years, and underlying malignancy [2,3].…”

Section: Introductionmentioning

confidence: 99%

MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation

Bosch¹,

Hoe

2000

European Radiology

View full text Add to dashboard Cite

show abstract

“…Adachi et al described an 1-year-old boy who developed VOD of liver after receiving vincristine (1.5 mg/m 2 given twice), actinomycin D (15 µg/kg given 5 times), and cyclophosphamide (600 mg/m 2 given once) [12]. Kanwar et al described a 3.8-year-old girl who developed hepatic VOD while receiving VAC regimen of the IRS-IV for parameningeal rhabdomyosarcoma [6]. D'Antiga et al reported 6 patients (4 Wilms tumor, 1 clear cell sarcoma, and 1 rabdomyosarcoma case) who developed hepatic VOD during treatment with actinomycin D and vincristine alone.…”

Section: Discussionmentioning

confidence: 98%

“…In the past two decades, VOD has been increasingly recognized as a complication of conventional chemotherapy with or without abdominal irradiation, which most frequently occurs in Wilms tumor cases 616 E. Cecen et al who received vincristine and actinomycin D [2][3][4]. But only few cases have been reported in children treated with same agents for rhabdomyosarcoma [5,6].…”

mentioning

confidence: 97%

VENO-OCCLUSIVE DISEASE IN A CHILD WITH RHABDOMYOSARCOMA AFTER CONVENTIONAL CHEMOTHERAPY: Report of a Case and Review of the Literature

Çeçen

Mutafoglu

Özgüven

et al. 2007

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

Although veno-occlusive disease of the liver is a well-known complication of high-dose chemotherapy and bone marrow transplantation, it has rarely been observed in children who receive conventional chemotherapy. Most cases in the literature consists of children with Wilms tumor. It has been very uncommon in rhabdomyosarcoma patients until recently, although they commonly receive similar anticancer agents. Here the authors report a 2-year-old boy with rhabdomyosarcoma who developed veno-occlusive disease while receiving VAC (vincristine, actinomycin D, cyclophosphamide) chemotherapy regimen according to the IRS-IV protocol. The patient gradually recovered during 2 weeks with supportive treatment only.

show abstract

“…Toxicity was more likely to occur early in treatment, although the incidence was lower in patients who tolerated their first course of therapy [9]. Other major risk factors appear to be the presence of Wilms tumour, as opposed to other tumour types, and Act D dose intensity [5, 10]. Bearing these factors in mind, it is a concern that for many well established drugs such as Act D, currently used dosing guidelines are founded largely on empirical experience, as opposed to being based on a sound knowledge of the clinical pharmacology of the drug.…”

Section: Introductionmentioning

confidence: 99%

Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer

et al. 2014

View full text Add to dashboard Cite

Background and ObjectiveDespite its important role in cancer treatment, there is currently very limited available information concerning the clinical pharmacology of actinomycin D (Act D). The study was designed to characterise Act D pharmacokinetics and investigate the impact of pharmacogenetic variation on Act D disposition in children with cancer.MethodsA total of 650 plasma samples collected over an 8 year period from 117 patients ≤21 years receiving Act D (0.4–1.6 mg/m2) were used to characterise a population pharmacokinetic model. Polymorphisms in ABCB1 were analysed in 140 patients.ResultsA 3-compartment model provided a good fit to the data. Median values for Act D clearance and volume of distribution in the central compartment (V1) obtained from the model were 5.3 L/h and 1.9 L (13.9 L/h/70 kg and 7.5 L/70 kg), respectively. There was substantial inter-subject variation in all pharmacokinetic parameters (coefficients of variation 53–81 % for non-normalised values). Body weight was a major determinant of Act D clearance, such that dose capping at 2 mg in larger children at a protocol dose of 1.5 mg/m2 resulted in significantly lower area under the plasma concentration-time curves (mean AUC values: 9.3 versus 12.8 mg·min/L; P < 0.0001). No significant relationships were found between ABCB1 genetic variants and Act D pharmacokinetic parameters, nor between CL, V1 or dose and incidence of grade 3 or 4 toxicity.ConclusionWe have defined the pharmacokinetics of Act D in a paediatric patient population, providing robust estimates of key pharmacokinetic parameters. Pharmacokinetic data bring into question the current clinical practice of dose capping at 2 mg in larger patients. Pharmacogenetic variation in candidate drug transporter genes identified from preclinical studies does not significantly impact on Act D exposure in a clinical setting.Electronic supplementary materialThe online version of this article (doi:10.1007/s40262-014-0153-2) contains supplementary material, which is available to authorized users.

show abstract

Veno‐occlusive Disease of the Liver After Chemotherapy for Rhabdomyosarcoma: Case Report With a Review of the Literature

Cited by 22 publications

References 24 publications

MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation

MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation

VENO-OCCLUSIVE DISEASE IN A CHILD WITH RHABDOMYOSARCOMA AFTER CONVENTIONAL CHEMOTHERAPY: Report of a Case and Review of the Literature

Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer

Contact Info

Product

Resources

About